Skip to content

Comparison of Follow-up Protocols in Terms of Fetal, Neonatal and Maternal Results in Intrauterine Growth Retardation

Comparison of Follow-up Protocols in Terms of Fetal, Neonatal and Maternal Results in Intrauterine Growth Retardation: a Randomised Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04141189
Enrollment
206
Registered
2019-10-28
Start date
2019-11-15
Completion date
2020-11-15
Last updated
2020-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal Surveillance, Intrauterine Growth Restriction

Keywords

Intrauterine Growth Restriction, fetal surveillance, fetal doppler, fetal growth

Brief summary

This study will be undertaken to determine whether the frequency of fetal surveillance can be safely reduced from bi-weekly to weekly in the case of fetusus with intrauterine growth restriction.

Detailed description

In this prospective randomized study, the cases whose fetal weight predicted by ultrasonography (USG) between the 28th and 37th weeks of gestation are below 10percentile according to the World Health Organization (WHO) normograms. The cases will be divided into two groups as group 1:weekly and group 2:bi-weekly (twice-weekly) The cases will be evaluated by fetal Doppler, amniotic fluid volume, nonstress test (NST) and maternal preeclampsia tests.Maternal severe hypertension/preeclampsia, category 3 NST, oligohydramnios (after 37 weeks amniotic fluid index \<5; after 34 weeks single deepest pocket \<2 cm) ,pathological doppler (before 34 weeks reverse flow in an umbilical artery , after 34 weeks absent end-diastolic flow in an umbilical artery) in cases of birth decision will be taken. Cases without the above mentioned complications will be delivered between 38 weeks 3 days and 39 weeks.

Interventions

PROCEDUREweekly

fetal surveillance frequency

PROCEDUREbi-weekly

fetal surveillance frequency

Sponsors

Bezmialem Vakif University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* 28-37 weeks pregnant women with estimated fetal weight below 10 percentile * singlton pregnancy

Exclusion criteria

* maternal preeclampsia * maternal systemic disease (pregestational diabetes, gestational diabetes mellitus a2, antiphospholipid antibody syndrome, chronic kidney disease) * oligohydramnios (after 34 weeks amniotic fluid index \<5; before 34 weeks single deepest pocket \<2 cm) * pathological doppler (high umbilical artery resistance index, absence of end-diastolic flow velocity in the umbilical artery, reverse flow in the umbilical artery, brain sparing effect in middle cerebral artery, abnormal ductus venosus flow)

Design outcomes

Primary

MeasureTime frameDescription
neonatal hospital stay3 monthsduration of neonatal hospital stay (days)

Secondary

MeasureTime frameDescription
antenatal hospital stay3 monthsduration of antenatal hospital stay (days)

Other

MeasureTime frameDescription
acidosis24 hoursfetal acidosis (normal cord-blood pH ranges from 7.14 to 7.4 during labor, values below 7.14 are considered to be acidosis)
gestational age at delivery24 hoursgestational age at delivery as days (e.g. 261days)
cesarean delivery24 hoursThe number of births by cesarean section
perinatal death3 monthsThe number of perinatal deaths. Perinatal death is a fetal death (stillbirth) or an early neonatal death (first 24 hours after birth)
neonatal hospital stay3 monthsduration of neonatal hospital stay (days)

Countries

Turkey (Türkiye)

Contacts

Primary Contacttaha takmaz, MD
thtkmz@hotmail.com+902124531700
Backup Contactserdar kutuk, MD
mehmetserdarkutuk@gmail.com+902124531700

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026